Abbott's Humira Defense May Be Linked To Counter-Suit In Massachusetts
Abbott is looking to the federal appeals court, and a district court in Massachusetts, to shore up its Humira franchise after a Texas jury issued a $1.67 billion verdict against it, finding that the firm's top-selling drug infringes a patent owned by Johnson & Johnson
You may also be interested in...
Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.